Evidence map›Paper›PMID 41430470›Full record

ArticleNature neuroscience2026

Axonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS.

Diana Piol, Bilal Khalil, Tessa Robberechts, Theo Killian, Maria Georgopoulou, Gabriele Partel, David Wouters, Nikolai Hecker, Paraskevi Tziortzouda, Yana Verresen and 11 more

Abstract read
In one paragraph

Article in Nature neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Diana PiolVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8089-0490
Bilal Khalil *VIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7251-4340
Tessa Robberechts *VIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Theo KillianVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Maria GeorgopoulouVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Gabriele PartelVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4482-3119
David WoutersKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8000-8023
Nikolai HeckerVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Paraskevi TziortzoudaVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Yana VerresenVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Nikky CorthoutVIB BioImaging Core Leuven, Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-1176-7277
Sam KintKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-6719-2903
Katy VandereykenKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4477-5866
Philip Van DammeLaboratory of Neurobiology, Department of Neuroscience, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4010-2357
Thierry VoetKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-1204-9963
Kristofer DavieVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2182-1249
Suresh PoovathingalKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.
Ludo Van Den BoschVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Stein AertsVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8006-0315
Alejandro SifrimKU Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.
Sandrine Da CruzVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, KU Leuven, Leuven Brain Institute, Leuven, Belgium. sandrine.dacruz@kuleuven.be.ORCID http://orcid.org/0000-0003-1986-4565

Funding

Muscular Dystrophy Association (Muscular Dystrophy Association Inc.) 1060285Muscular Dystrophy Association (Muscular Dystrophy Association Inc.) 962700
6 · The paper itself

Abstract

Local protein synthesis is vital for neuronal function, but its dysregulation in neurodegenerative diseases remains poorly defined. Here we applied spatial transcriptomics to adult mouse motor nerve axons and cell bodies to enable subcellular mapping. Among transcripts found in mature axons, the most enriched biological process is protein translation, and localization of translation machinery was confirmed using multiplexed single-molecule spatial transcriptomics combined with immunofluorescence. Amyotrophic lateral sclerosis (ALS)-associated mutations in the RNA-binding protein fused in sarcoma (FUS), which suppress local translation, disrupt the compartment-specific RNA signatures, including components of the translation machinery. In particular, eukaryotic initiation factor 5a (Eif5a), a translation factor involved in elongation and termination, is found to be locally impaired in mutant FUS axons with reduced levels of its active hypusinated form. Axon-specific treatment with polyamine spermidine restores Eif5a hypusination and ameliorates mutant FUS-dependent neuronal defects, including suppression of local protein synthesis. Finally, in vivo spermidine treatment reduces ALS-related toxicity in mutant FUS and TDP-43 Drosophila models, which may have implications for therapy development.

Indexed as

Amyotrophic Lateral SclerosisAxonsPeptide Initiation FactorsProtein BiosynthesisRNA-Binding Protein FUSRNA-Binding ProteinsAnimalsDrosophilaEukaryotic Translation Initiation Factor 5AMiceMice, TransgenicMotor NeuronsMutationEukaryotic Translation Initiation Factor 5AFUS protein, mousePeptide Initiation FactorsRNA-Binding Protein FUSRNA-Binding Proteins

Identifiers

PMID41430470
PMCPMC12779556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.